ArticleIMA fungus2021
A revision of malbranchea-like fungi from clinical specimens in the United States of America reveals unexpected novelty.
Article in IMA fungus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Verweija noviomagensis gen. sp. nov.-A novel member of the Onygenales incertae sedis isolated from a dystrophic nail.Medical mycology · 2026Article
- Soil ascomycetes from Spain. XV. New and noteworthy fungi from Gran Canaria Island (Canary Islands archipelago).Studies in mycology · 2026Article
- Novel Freshwater Ascomycetes from Submerged Plant Debris in the Zújar River (Extremadura Community, Spain).Journal of fungi (Basel, Switzerland) · 2026Article
- Two new soil-inhabiting fungi,MycoKeys · 2026Article
- Phylogenetic and ecological drivers of the avian lung mycobiome and its potentially pathogenic component.Communications biology · 2025Article
- IMA fungus · 2025Article
- Fungal Planet description sheets: 1697-1780.Fungal systematics and evolution · 2024Article
- Genomic Sequencing and Functional Analysis of the Ex-Type Strain ofJournal of fungi (Basel, Switzerland) · 2024Article
- 200 years of taxonomic confusion: Sporendonema and allies.Antonie van Leeuwenhoek · 2024Article
- Insights into Some Onygenalean Fungi from Freshwater Sediments in Spain and Description of Novel Taxa.Journal of fungi (Basel, Switzerland) · 2023Article
- Eight novel cave fungi in Thailand's Satun Geopark.Fungal systematics and evolution · 2023Article
- Name Changes for Fungi of Medical Importance, 2020 to 2021.Journal of clinical microbiology · 2023Review
- Unravelling the fungal darkness in a tropical cave: richness and the description of one new genus and six new species.Fungal systematics and evolution · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
The fungi of the order Onygenales can cause important human infections; however, their taxonomy and worldwide occurrence is still little known. We have studied and identified a representative number of clinical fungi belonging to that order from a reference laboratory in the USA. A total of 22 strains isolated from respiratory tract (40%) and human skin and nails (27.2%) showed a malbranchea-like morphology. Six genera were phenotypically and molecularly identified, i.e. Auxarthron/Malbranchea (68.2%), Arachnomyces (9.1%), Spiromastigoides (9.1%), and Currahmyces (4.5%), and two newly proposed genera (4.5% each). Based on the results of the phylogenetic study, we synonymized Auxarthron with Malbranchea, and erected two new genera: Pseudoarthropsis and Pseudomalbranchea. New species proposed are: Arachnomyces bostrychodes, A. graciliformis, Currahmyces sparsispora, Malbranchea gymnoascoides, M. multiseptata, M. stricta, Pseudoarthropsis crassispora, Pseudomalbranchea gemmata, and Spiromastigoides geomycoides, along with a new combination for Malbranchea gypsea. The echinocandins showed the highest in vitro antifungal activity against the studied isolates, followed by terbinafine and posaconazole; in contrast, amphotericin B, fluconazole, itraconazole and 5-fluorocytosine were less active or lacked in vitro activity against these fungi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.